Skip to main content

Recent News & Research

Onc Live
ResearchTreatments

Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC

*September 2020* Note: this is in context of HER2, another resistance mechanism of EGFR TKIs. Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi. According to data from the phase 2 DESTINY-Lung01 trial, trastuzumab deruxtecan induced a confirmed objective response rate of…
laurabbook@gmail.com
October 16, 2020
ResearchTreatments

First Drug for MET+ NSCLC Shows High Response Rates

*September 2020* The first targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) harboring MET mutations, capmatinib (Tabrecta), has shown deep and durable responses, conclude investigators of the pivotal trial that led to the drug's approval. Responses were seen in all patients regardless of how many previous drugs…
laurabbook@gmail.com
October 16, 2020
MEDPAGE TODAY
ResearchTreatments

Drug Active in ‘Undruggable’ KRAS-Mutant NSCLC

*September 2020* A small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients with non-small cell lung cancer (NSCLC). A third of patients with NSCLC had objective responses with sotorasib, and 88.1% attained disease control. The disease control rate (DCR) surpassed 90% in…
laurabbook@gmail.com
October 16, 2020
Onc Live
ResearchTreatments

BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models

*September 2020* Additionally, the findings showed that BLU-945 potently and selectively inhibited triple-mutant EGFR, harboring the most common on-target resistance mutations to standard EGFR-targeted therapies, including the third-generation EGFR TKI osimertinib (Tagrisso). Specifically, BLU-945 inhibited triple-mutant EGFR with sub-nanomolar potency and it also showed a greater than 900-fold selectivity over…
laurabbook@gmail.com
October 16, 2020
Onc Live
ResearchTreatments

EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC

*September 2020* The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib (Tagrisso)-resistant patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to findings from the phase 1 CHRYSALIS study that were presented during the 2020 ESMO Virtual Congress.…
laurabbook@gmail.com
October 16, 2020
Coping With Cancer

How Do I Handle This Cancer Part 5

*October 2020* by Tess Taft, msw, licsw ©all rights reserved This is the fifth part of a seven-part series on how people cope with cancer. The first installment discussed GRIEF, DEPRESSION, and ANXIETY. The second installment included thoughts on ANGER.The third installment spoke to people who manage their feelings by WITHDRAWAL and RESIGNATION. The fourth part addressed how people…
laurabbook@gmail.com
October 16, 2020